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Backgound
The purpose of this study was to assess the biological and clinical effects of n-acetyl-cysteine
(NAC) in Parkinson’s disease (PD).

Methods
The overarching goal of this pilot study was to generate additional data about potentially
protective properties of NAC in PD, using an in vitro and in vivo approach. In preparation for
the clinical study we performed a cell tissue culture study with human embryonic stem cell
(hESC)-derived midbrain dopamine (mDA) neurons that were treated with rotenone as a
model for PD. The primary outcome in the cell tissue cultures was the number of cells that
survived the insult with the neurotoxin rotenone. In the clinical study, patients continued
their standard of care and were randomized to receive either daily NAC or were a waitlist
control. Patients were evaluated before and after 3 months of receiving the NAC with
DaTscan to measure dopamine transporter (DAT) binding and the Unified Parkinson’s
Disease Rating Scale (UPDRS) to measure clinical symptoms.

Results
The cell line study showed that NAC exposure resulted in significantly more mDA neurons
surviving after exposure to rotenone compared to no NAC, consistent with the protective
effects of NAC previously observed. The clinical study showed significantly increased DAT
binding in the caudate and putamen (mean increase ranging from 4.4% to 7.8%; p<0.05 for
all values) in the PD group treated with NAC, and no measurable changes in the control
group. UPDRS scores were also significantly improved in the NAC group (mean improvement of 12.9%, p = 0.01).
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Conclusions
The results of this preliminary study demonstrate for the first time a potential direct effect of
NAC on the dopamine system in PD patients, and this observation may be associated with
positive clinical effects. A large-scale clinical trial to test the therapeutic efficacy of NAC in
this population and to better elucidate the mechanism of action is warranted.

Trial Registration
ClinicalTrials.gov NCT02445651

Introduction
Parkinson’s disease (PD) is a devastating neurodegenerative disorder involving the dopamine
system that affects more than a million Americans [1]. Standard of care medical treatments for
PD are limited to medications that focus on symptom management. Unfortunately, to date no
medication has been shown to slow progression in PD. Some supportive therapies such as exercise have shown improved quality of life [2,3], but there is a significant need to continue
exploring therapies that might improve symptoms and positively impact the disease process.
PD patients often seek adjunct therapies such as dietary supplements, even though most have
little to no supportive data [4,5]. Testing those products that have at least a theoretical rationale
congruous with what is known of the pathophysiology of PD could have value for patients and
providers.
A number of studies have suggested the importance of oxidative stress in the pathophysiology of PD. Oxidative stress itself is defined as a redox imbalance in which there is an excess formation of oxidants or a decrease in the amount of function of natural antioxidants [6]. The
brain especially has difficulty withstanding substantial amounts of oxidative stress because of
the presence of high amounts of polyunsaturated fatty acids, low levels of antioxidants such as
glutathione, and increased iron content in specific areas such as the globus pallidus and the
substantia nigra (SN) [7]. In addition, since neurons are in a post-mitotic state, they are
unlikely to recover from an oxidative stress insult.
Given the potential importance of oxidative stress in PD, this study focused on n-acetyl cysteine (NAC), which is known to possess substantial antioxidant properties. NAC is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine, and works primarily by helping
restore the body’s natural antioxidant, glutathione. NAC is available over-the-counter as an
oral supplement and also is available as an injectable pharmaceutical that is primarily used to
protect the liver in acetaminophen overdose. We used the combination of oral and IV forms
because oral absorption is relatively low (6–10%) and variable [8,9]. Furthermore, an MRS
study of 3 patients with PD showed that blood glutathione increased after the start of an NAC
infusion and reached a maximum at approximately 60 to 75 minutes [10]. Brain glutathione
also increased with maximal values observed at approximately 90 to 110 minutes. Subjects who
had the greatest percent change in blood glutathione after NAC infusion also had the greatest
percent change in brain glutathione. Interestingly, none of the subjects returned to their baseline brain glutathione levels even at 120 minutes after NAC infusion. Since glutathione itself
inefficiently crosses the blood-brain barrier [11], the results of this small study of PD patients
suggest that NAC might be useful in increasing brain glutathione levels and thereby impact
oxidative processes in the brain.
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The goal of the present study was to explore the effects of NAC using both an in vitro and in
vivo approach. To find supportive data for the pilot clinical study, we performed a cell line tissue culture study in which we used a model of PD that employs midbrain dopamine (mDA)
neurons generated from human embryonic stem cells (hESCs) [12] to determine whether NAC
can protect these mDA neurons from damage resulting from exposure to increasing doses of
the PD-like neurotoxin, rotenone. Not only did we hope that this cell line study would be supportive of our clinical trial described below, but it would also corroborate other studies of the
protective effect of NAC in animal dopamine cell line studies.
In the clinical study, we measured dopamine transporter (DAT) binding using SPECT with
I-123 Ioflupane (DaTscan) before and after receiving NAC for three months. It has been
shown that the regional concentration of DAT tends to reflect the tone of the dopamine nervous system in that area [13,14] and is significantly reduced in PD patients [15–17]. DaTscan
is approved for clinical use in the US and a number of research studies have shown that DaTscan is able to differentiate PD from controls [18,19]. DaTscan has also been shown to correlate
with disease severity [20,21] and has been used in previous trials of PD treatment effects. The
Unified Parkinson’s Disease Rating Scale (UPDRS) was also performed on the same day as the
DaTscan as a measure of clinical symptoms.
Although this was a pilot study, our goal was to demonstrate whether 1) administration of
NAC over three months would result in improved dopamine function as reflected in increased
DAT binding on the DaTscan and clinical symptoms as measured by the UPDRS, and 2) confirm that NAC would have a neuroprotective effect in cultures of hESC-derived mDA neurons
treated with rotenone.

Materials and Methods
Cell Line Study
The human embryonic stem (hES) cell line (H9) (#WA09) were purchased from Wicell (University of Wisconsin, Madison, WI) and maintained according to the supplier’s instructions.
Briefly, cells were grown on Geltrex (Life Tech) coated tissue culture plates in mTeSR1 medium
(Stem cell Technology). Cell propagation was achieved through manual dissection and transfer
of cell colonies every 4 to 5 days. The mDA differentiation process was initiated by passaging
them on Geltrex-coated tissue culture plates with two TGF/BMP inhibitors 10 μM SB431542
(Tocris) and 2 μM Dorsomorphin (Tocris), together with 100ng/ml SHH (R&D Systems) and
200nM Purmorphamine (Tocris) for 1 week. Then neural progenitors (NPs) were generated in
N2/B27 NEP-basal medium supplemented with FGF8 (R&D Systems) and 20 ng/ml SHH for 1
week. NPs were then expanded in NEP-basal medium supplemented with 20ng/ml bFGF (R&D
system) for another week. For further differentiation down the mDA pathway, cells were incubated for 1 week in NEP-basal medium supplemented with 1mM dibutyryl cAMP (Sigma).
mDA neurons were pretreated with 10 μM N-Acetyl Cysteine (AllergyResearchGroup) for 3
days and challenged with 15nM, 30nM rotenone (Sigma) for 24 hours. Then cells were fixed
and stained for dopaminergic neuron marker tyrosine hydroxylase (TH, 1:200, Pel-freze). Tyrosine hydroxylase is the first and rate limiting enzyme in the production of dopamine. It is highly
specific to brain catecholamine neurons. As such, it is the most commonly used marker of midbrain dopamine neurons. Importantly, however, the differentiation protocol used in this study
has been previously shown by us [12] and others [22] to give rise to midbrain fated neural progenitors that coexpress both Lmx1a and Foxa2 fate genes and that differentiate into TH+ neurons midbrain dopamine neurons. TH+ cells were counted and averaged over 5 randomly
chosen fields/culture in each treatment using Image J in a Nikon confocal microscope. All data
was normalized to 100% (untreated control). Unpaired t-test was used for statistical analysis.
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Human Subjects
Written informed consent, approved by the Institutional Review Board of Thomas Jefferson
University, was obtained from all subjects and the study was registered on trials.gov with the
following identifier: NCT02445651. Of note, there was an administrative delay in registering
the IRB approved study (approved on March 13, 2014) on trials.gov until December 2014 The
authors confirm that all ongoing and related trials for this drug/intervention are registered.
Subjects were recruited from the neurology offices of two co-authors (DK and TWL) who are
the co-directors of the Movement Disorder Clinic at Thomas Jefferson University. All subjects
were enrolled and had their 3 month follow up between June 26, 2014 and August 13, 2015.
Subjects were required to meet the standard clinical diagnosis of PD along with the following
inclusion criteria: Age 40–80 years old; physically independent; Hoehn and Yahr score of I-III
inclusive; and on stable medication regimen for at least one month. Patients were excluded for
the following: Known allergy to iodine or NAC; previous brain surgery; score on Mini-Mental
Status examination of 25 or lower; intracranial abnormalities (e.g., stroke, tumor, vascular
abnormality); history of head trauma with loss of consciousness > 48 hours; any medical disorder or physical condition that could reasonably be expected to interfere with the assessment of
parkinsonian symptoms, or with any of the study assessments including the SPECT imaging;
evidence of a significant psychiatric disorder including current alcohol or drug abuse; and
female patients who were pregnant or lactating. Subsequently, a full history, physical and neurological examination was performed. Subjects that continued to qualify for the study then
underwent an initial DaTscan SPECT study along with qualitative evaluation of their clinical
symptoms using the UPDRS.

NAC Intervention
Subjects were then randomized using a permuted block method (1:1 ratio using sealed envelopes with the allocation) to either receive intravenous/oral NAC or were placed in the waitlist
control condition (see Fig 1). For three months both groups continued their current standard
of care PD treatment, with the experimental group receiving NAC, as described below. Additional control subjects included study patients who had an initial SPECT scan 3–6 months
prior to entering the study that were compared to the pre-NAC scan.
The NAC was obtained from the Jefferson Pharmacy as Acetadote (Cumberland Pharmaceuticals). Pharmaceutical NAC is an intravenous (IV) medication most commonly used for
the treatment of acetaminophen overdose. Acetylcysteine is the nonproprietary name for the
N-acetyl derivative of the naturally occurring amino acid, L-cysteine (N-acetyl-L-cysteine,
NAC). Acetadote is supplied as a sterile solution in vials containing 200 mg/mL acetylcysteine.
The pH of the solution ranges from 6.0 to 7.5. Acetadote contains the following inactive ingredients: 0.5 mg/mL disodium edetate, sodium hydroxide (used for pH adjustment), and Sterile
Water for Injection, USP. Acetadote doses were prepared for each patient by a trained study
nurse. The dose was 50mg/kg mixed into 200ml of D5W infused over approximately one hour
1x per week. Subjects took the 600mg NAC tablets 2x per day on the days that they did not
receive the IV NAC.
After approximately 90 days of receiving oral and IV NAC or being in the waitlist condition,
subjects underwent a follow up evaluation, including repeat UPDRS along with the DaTscan
SPECT.

DaTscan SPECT Imaging Procedure
Subjects received a DaTScan before and after completing the NAC for 90 days. Approximately
30 minutes prior to injection of the DaTscan, the patients were given an oral dose of lugol’s
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Fig 1. CONSORT Flow Diagram.
doi:10.1371/journal.pone.0157602.g001

solution, which is standard practice for these scans. DaTscan (4–5 mCi, ± 20%) was then
injected intravenously through a previously placed catheter. After injection of the DaTscan, the
venous catheter was removed. SPECT images were acquired at 3 hours post injection for
approximately 45 minutes. This enabled us to obtain qualitative and semiquantitative regional
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uptake values as determined by our previously described reference region method (see below)
[23]. All scans were performed on a Philips Forte gamma camera equipped with ultra-high resolution collimators. All the images were reconstructed using filtered back projection with
Chang's first order attenuation correction.

Data Analysis and Statistics
Manual demarcation of brain regions: A set of standardized templates containing small regions
of interest (ROIs) were fit on each DaTscan for the caudate and putamen bilaterally [23].
Within the x-y plane, the ROIs in the template were smaller than the actual structures they represent in order to minimize resolution-induced problems with ill-defined edges. To reduce the
effects of volume averaging, the ROIs were not placed on the slices that contained the upper
and lower most portions of the structures they represent. The primary outcome measure was
the distribution volume ratio (DVR) at 3 to 4 hours post administration, when the distribution
of DaTscan has approached a transient, near equilibrium like state that reflects the ratio of k3/
k4, which is related to binding potential. This allows for a quantitative assessment of DAT
binding. Thus, scanning at this time allows for semiquantitative analysis using a ROI analysis
with a background region as an index of nonspecific binding. In addition, an ROI was placed
on the midbrain region where DaTscan binding reflects serotonin transporter (SERT) binding
as a secondary imaging measure of the effects of the NAC. DaTscan, while not the most specific
measure of SERT binding, can reliably evaluate SERT binding due to the non-selective nature
of DaTscan and the presence of SERT primarily in the midbrain [24].
Separate linear mixed effects (LME) models with random patient effect were used to model
(i) pre- and post-Tx dopamine transporter binding measures from left and right caudate and
left and right putamen; (ii) pre- and post-Tx UPDRS measures; and (iii) pre- and post-Tx midbrain serotonin transporter binding measures (Tx refers to NAC plus standard of care of just
standard of care without NAC). The LME is adjusted for correlation of the repeated measures
from the same patient. The candidate fixed effects predictors included Tx group (NAC vs. Control; N vs. C), age, gender and UPDRS measures in the models for dopamine and serotonin
transporter binding measures. The final models were obtained by backward elimination of
nonsignificant fixed effects predictors. The association between the pre-to-post-Tx change in
UPDRS, dopamine transporter binding in caudate and putamen, and serotonin transporter
binding in the midbrain, was evaluated using Pearson correlation coefficients with the corresponding 95% confidence intervals. For confirmation of the DVR analysis, we also performed a
paired t-test in Statistical Parametric Mapping software (SPM8; Welcome Department of Cognitive Neurology, University College, London, UK), implemented in Matlab (MathWorks,
Natick, Massachusetts). Images were initially normalized using the ioflupane template developed by García-Gómez et al [25]. For our preliminary study, scans from the NAC group were
evaluated using a paired t test between the pre and post NAC scans with the threshold set at
p<0.05 and minimum of 50 pixel cluster.

Results
Cell Line Data
The results from the cell line study demonstrated that when the mDA neurons derived from
hESCs were pretreated with NAC, there was an overall protective effect from both 15 and 30
nM rotenone (see Fig 2). Specifically, the percentage of surviving TH+ neurons after exposure
to Rotenone was significantly higher in the NAC treated cells compared to the untreated cells
(63% in NAC compared to 39% in untreated for 15nM rotenone and 40% in NAC compared
to 22% in untreated for 30nM rotenone).
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Fig 2. mDA neurons derived from hESCs were treated with N-acetyl cysteine at 10 μM for 3 days
before challenge with rotenone (15nM and 30 nM) for 24 hours. TH+ neurons were quantified after cells
were fixed and stained. Data was normalized as percentage of surviving mDA neurons compared to
untreated control (100%). Treatment groups were compared with rotenone only groups using unpaired t-test.
* p<0.05, ** p<0.01.
doi:10.1371/journal.pone.0157602.g002

Human Study Demographics
For the human subjects study, twenty-three patients with a clinical diagnosis of PD were
enrolled for this preliminary assessment, with 12 patients randomized to the NAC arm and 11
patients to the waitlist control arm. There were no patients that dropped out of the study and
no significant adverse events. Baseline clinical data for the two groups are presented in Table 1,
and were not significantly different.

Imaging and UPDRS Results
Although preliminary, there were a number of statistically significant findings that warrant further evaluation in larger clinical trials. Table 2 provides mean pre- and post-Tx dopamine
transporter binding measures in each Tx group and each ROI (caudate or putamen). The mean
pre-to-post Tx change was positive and significant in the group with Tx = N for both the caudate or putamen (Table 3). In the control group, the mean pre-to-post Tx change was not significantly different from zero for the caudate and significantly negative for the putamen
(Table 3). The Pre-to-Post Tx changes in both the caudate or putamen were significantly
higher in the Tx group N as compared to controls (Tx group C) (Table 3). The findings are
confirmed using the paired t test results in SPM8 (see Fig 3).
Table 1. Demographics for the study subjects per group.
NAC Group
Gender

Control Group

6M/6F

5M/6F

Age (Mean±SD)

59.6±8.2

62.9±7.6

Duration of PD (mean years±SD)

3.4±2.2

3.4±1.8

Hoen and Yahr (Mean±SD)

1.8±0.5

1.6±0.5

8/4

6/5

On/Off Carbidopa/Levodopa
doi:10.1371/journal.pone.0157602.t001
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Table 2. Mean pre- and post-Tx dopamine transporter binding measures.
Group

ROI

Time

Mean

LCL95%

UCL95%

C
C

caud

pre-Tx

2.85

2.64

3.06

put

pre-Tx

1.80

1.59

C

2.02

caud

post-Tx

2.77

2.55

2.98

C

put

post-Tx

1.66

1.45

1.88

N

caud

pre-Tx

2.60

2.40

2.81

N

put

pre-Tx

1.64

1.44

1.84

N

caud

post-Tx

2.75

2.55

2.96

N

put

post-Tx

1.77

1.56

1.97

doi:10.1371/journal.pone.0157602.t002
Table 3. Mean pre-to-post-Tx differences in dopamine transporter binding.
Comparison

Mean Difference

LCL95%

UCL95%

p-value

Caud pre-to-Post Tx change in group N

0.15

0.03

0.27

0.014

Put pre-to-Post Tx change in group N

0.12

0.01

0.24

0.039

Caud pre-to-Post Tx change in group C

-0.09

-0.21

0.04

0.171

Put pre-to-Post Tx change in group C

-0.14

-0.26

-0.02

0.027

Caud pre-to-Post Tx change in group N vs. C

0.23

0.06

0.41

0.007

Put pre-to-Post Tx change in group N vs. C

0.26

0.09

0.43

0.003

doi:10.1371/journal.pone.0157602.t003

Table 4 provides estimated pre- and post-Tx mean UPDRS Total Scores in each Tx group.
The negative pre-to-post Tx change was significant in the group with Tx = N, but not in the
group with Tx = C, and the difference between Tx groups N and C was not significant in terms
of the Pre-to-Post Tx changes (Table 5). The model also implies that UPDRS total scores are
higher for gender = M as compared to gender = F.
Although a secondary measure, we also found significant changes in midbrain serotonin
transporter binding in the NAC group. The control group essentially did not change going
from an initial mean value of 1.53 (95% CI: 1.42,1.63) to 1.51 (95%CI: 1.40, 1.61) while the
NAC group went from an initial mean value of 1.48 (95% CI: 1.37,1.58) to 1.65 (95%CI: 1.55,
1.75). The change observed between the NAC group was significant with a p = 0.01 and was
also significantly different from controls (p = 0.045). The model also implies that serotonin
transporter binding is decreasing with age by 0.008 per year (95%CI: 0.0002, 0.016), consistent
with prior studies.
Importantly, there was a significant correlation observed between the change in UPDRS
scores and the change in dopamine transporter binding in the caudate (Pearson correlation
coefficient of -0.45, CI: -0.73, -0.05, p = 0.026) and putamen (Pearson correlation coefficient of
-0.54, CI: -0.78, -0.17, p = 0.006).

Discussion
A number of studies have suggested the importance of oxidative stress in the pathophysiology
of PD. Oxidative stress itself results from either excess formation of oxidants or a decrease in
the amount of function of antioxidants [26], which in the case of PD may potentially damage
key cellular components such as lipids, proteins, and DNA. Evidence for oxidative damage in
the brain of PD patients includes the finding of an increase in the amount of lipid peroxidation
products such as malondialdehyde and 4-hydroxynonenal, an increase in protein oxidation as
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Fig 3. Pre and post NAC DaTscans (left and right respectively) from one particularly responsive patient (A)
shows a substantial increase in dopamine transporter binding in the basal ganglia (arrows). We also present
(B) the paired t test results overlaid onto a standard MRI template using SPM8 software showing significantly
greater binding (p<0.05) post NAC in the basal ganglia.
doi:10.1371/journal.pone.0157602.g003

evidenced by protein cross-linking and fragmentation, and an increase in the concentration of
8- hydroxy-20 -deoxyguanosine, a product of DNA oxidation [7].
Additional evidence suggests that reactive oxygen species (ROS) are derived from dopamine
itself, which is chemically unstable and undergoes auto-oxidation to form dopamine quinones
(DAQs) and superoxide anion radicals. The DAQs can further act as oxidants thus supporting
ROS formation. Auto-oxidation of dopamine may be increased in the early stages of PD when
dopamine turnover is increased to compensate for dying dopaminergic neurons [27].
Glutathione, an important reducing agent in the neurons, has been found to be depleted in
the brain of PD patients [28] and the magnitude of glutathione depletion appears to parallel
the severity of the disease and is the earliest known indicator of nigral degeneration, apparently
preceding detectable losses in striatal dopamine [29,30]. The brain has difficulty withstanding
Table 4. Mean pre- and post-Tx UPDRS Total Score.
Group

Time

Mean

LCL95%

UCL95%

C

pre-Tx

20.2

15.4

24.9

C

post-Tx

22.2

17.4

26.9

N

pre-Tx

25.6

21.1

30.1

N

post-Tx

22.3

17.8

26.9

doi:10.1371/journal.pone.0157602.t004
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Table 5. Significant predictors of UPDRS Total Score.
Comparison
Gender M vs. F

Mean Difference

LCL95%

UCL95%

p-value

9.62

3.26

15.99

0.005

Pre-to-Post Tx change in group N

-3.25

-5.33

-1.17

0.004

Pre-to-Post Tx change in group C

-2.00

-4.17

0.17

0.069

Pre-to-Post Tx change in group N vs. C

-1.25

-4.26

1.76

0.397

doi:10.1371/journal.pone.0157602.t005

substantial amounts of oxidative stress because of the presence of high amounts of polyunsaturated fatty acids, low levels of antioxidants such as glutathione, and increased iron content in
specific areas such as the globus pallidus and the substantia nigra (SN) [7].
An additional component to the relationship between oxidative stress and PD is related to
alpha-synuclein, a prominent component of Lewy body aggregates [31] which are a pathological hallmark of PD. Previous studies have implicated the role of oxidative stress in the formation of synuclein aggregates [32,33]. In addition, several studies have suggested that ironrelated oxidative stress can promote α-synuclein aggregation [34,35]. Furthermore, soluble
nitrated α-synuclein, which results from interactions with oxidated nitrogen species, appears
to activate microglia to produce substantial amounts of ROS through modulation of specific
ion channels [36].
Thus, there appears to be growing evidence that oxidative stress likely plays a prominent
role in the pathophysiology of PD. When enough oxidative stress occurs, the cell can no longer
protect itself resulting in dysfunction and ultimately cell death. The question is whether interventions designed to restore the redox potential will be effective in attenuating the disease
process.
NAC is an over-the-counter antioxidant supplement and also is available as an injectable
pharmaceutical that protects the liver in cases of acetaminophen overdose. Our cell line study
is consistent with other laboratory studies that have suggested how NAC might have a beneficial effect in neurodegenerative disorders such as PD. For example, older studies showed that
cotreatment with NAC rescued rat pheochromocytoma cells from the toxic effect of dopamine
combined with buthionine sulfoximine, an inhibitor of gamma-glutamyl transpeptidase, or
phoron a substrate of glutathione transferase [37]. A more recent study showed that NAC may
reduce misfolded protein levels and ameliorate proteotoxicity through heat shock proteins
[38]. The authors suggested that their findings broaden the potential mechanisms of action for
NAC in neurodegenerative proteinopathies. Another study tested the hypotheses that a combined exposure of nerve cells to oxidative stress caused by hydrogen peroxide and paraquat
would elicit synergistic neurodegeneration and that this toxicity would be prevented by NAC
[39]. The findings revealed that when neuronal N2a cells received two hits of hydrogen peroxide the result was a severe loss of glutathione that was attenuated by NAC. In fact, NAC
reduced the near-complete loss of cells after exposure to dual hydrogen peroxide hits.
NAC can prevent oxidative damage and cell death in an in vitro model that disrupts mitochondrial electron transport function. Thus, NAC could act in vivo against programmed cell
death in PD [40]. Long-term treatment with NAC alters NF-kappaB signaling in the brain of
mice by increasing cytoplasmic retention of NF-kappaB. This prevents the action of NF-kappaB as a transcription factor in the nucleus [41]. Since increased activation of NF-kappaB may
contribute to the pathology in models of Parkinson’s disease, it is possible that the modulating
effect of NAC on NF-kappaB activity may be another mechanism by which NAC helps patients
with PD [42,43].
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Another interesting study showed that NAC is a potent scavenger of both H2O2 and toxic
quinones that are derived from dopamine which can contribute to cell death in PD. NAC also
prevented dopamine-mediated inhibition of Na+, K+-ATPase activity suggesting another
mechanism for the use of NAC in the treatment of PD [44]. If NAC prevents Na+, K+-ATPase
inhibition, it might counteract intracellular damage that leads to dopaminergic neuron death.
A study of rat neurons found that NAC reduced methamphetamine induced neurotoxicity in
dopaminergic neuronal cells (N27 cells) [45]. Thus, NAC prevents the methamphetamine
induced mitochondrial dysfunction and enhanced oxidative stress that induces apoptotic cell
death as well as oxidative stress markers.
Administration of NAC has been shown to increase glutathione levels in the mouse brain
[46,47]. NAC also has been shown to reduce markers of oxidative damage [48], increase mitochondrial Complex I activity in nerve cells [49], and protect against dopamine cell death from
MPTP toxicity [50–52]. In a mouse study, oral NAC was observed to protect dopaminergic terminals against loss related to over-expression of α-synuclein [41]. In α-synuclein over-expressing mice, NAC administration was associated with increased striatal tyrosine hydroxylase
positive terminal density and a decrease in α-synuclein immuno-labeling. In addition, NAC
administration significantly increased glutathione concentrations in the substantia nigra of
mice over-expressing α-synuclein.
Our cell line tissue culture data corroborates the above studies showing that pretreatment
with NAC protects mDA neurons derived from hESCs from exposure to rotenone. Thus, this
data supports the clinical and DaTscan data in PD patients given NAC. It should also be noted
that a major advantage of this approach, compared to other cell and animal studies, is the use
of a human rather than rodent cell line model of PD. Moreover, the results can suggest future
approaches that could be adapted to test the effects of other molecules on mDA neurons from
patient-derived human induced pluripotent stem cells (hiPSCs).
The clinical component of the current study supports other preliminary work. For example,
the effect of glutathione in PD was tested in a previous randomized double blind placebo controlled study of 21 PD patients that were not adequately controlled on medication showing a
modest effect in symptoms that trended towards significance [53]. We theorized based on the
above literature and our own studies that NAC might be more efficient. In addition, an important additional step in the current study was to go beyond a clinical measure such as the
UPDRS, and evaluate DAT binding as a physiological marker. Overall, it was highly encouraging to observe substantial changes over such a short period of time, suggesting additional timelines for future studies.
Although a secondary aim, we did find significantly increased SERT binding in the midbrain after NAC supplementation. While some previous studies, including our own, have
shown a relationship between SERT binding and depression [54,55], we excluded patients with
major depression in the current study, and our patients did not generally report significant
depressive symptoms. Thus, the meaning of the SERT binding change is unclear. However,
future studies might consider testing NAC in PD patients who specifically express significant
depressive symptoms to more carefully screen for depressive symptomatology.
There are several important limitations to the current study. Although we randomized
patients and included a control group, it was not a blinded study. It is possible that the
improvements that we observed in the NAC group could be related to the placebo effect due to
the use of the intravenous injection. Studies have documented a relatively strong placebo effect
in Parkinson’s disease patients. For example, in a report by Goetz et al., 11 studies of medical
and surgical interventions for PD were evaluated [56]. The authors found that the placebo
effect in medication related studies was a mean of 16% with a range from 0–27%. Surgical
interventions had a higher mean placebo response of 42%. Future studies comparing NAC to a
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placebo would help to clarify this issue. In addition, DaTscan and related tracers have been utilized for the evaluation of different therapeutic interventions [57,58] although some concerns
have been raised regarding the uniformity of DaTscan findings in multisite trials of different
medical interventions in PD [59,60]. However, despite such potential limitations, we felt that
DaTscan was an excellent first step for evaluating whether NAC supplementation as described
in this study, supports dopamine function in the brain of PD patients. It is also possible that
the administration of NAC has a pharmacological effect on the DAT concentration or DAT
binding. However, no such effect has been reported and while we observed a mean increased
DAT binding in the NAC group, it was not consistent across all subjects.
It should also be noted that the current study provided the NAC as both an IV and oral supplement. It is known that the IV administration of NAC results in substantially higher concentrations of NAC in the plasma. However, it is not known whether these higher concentrations
are required for any clinical or physiological effect in PD. Future studies might provide some
patients with more IV doses of NAC versus only the oral NAC to determine which route and
dose of administration might provide an optimal effect. Overall, this was a pilot study designed
to generate hypothesis-testing data that could inform clinical trials adequately powered to
assess safety and efficacy [61].
Overall, the current study using both cell line data and human data with DaTscan SPECT
suggests that NAC might positively impact dopamine function and potentially clinical symptoms. Future, randomized double blind, placebo controlled trials will be necessary to confirm
such an effect in PD patients.
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